2019
Phase 1, first-in-human study of TRAIL receptor agonist fusion protein ABBV-621.
Ratain M, Doi T, De Jonge M, LoRusso P, Dunbar M, Chiney M, Motwani M, Glasgow J, Petrich A, Rasco D, Calvo E. Phase 1, first-in-human study of TRAIL receptor agonist fusion protein ABBV-621. Journal Of Clinical Oncology 2019, 37: 3013-3013. DOI: 10.1200/jco.2019.37.15_suppl.3013.Peer-Reviewed Original ResearchDose escalationDose-limiting toxicityBlood-based markersECOG 0Prior regimensStable diseaseAcceptable toxicityMedian durationRespiratory failureMedian agePartial responseColorectal cancerPancreatic cancerBlood bilirubinBayesian continual reassessment methodPD markersContinual reassessment methodHuman studiesDay 1Solid tumorsTumor typesPK studiesTumor modelAntitumor activityApoptotic cell death
2015
First-in-human, dose-escalation, safety, and PK study of a novel 5T4-ADC in patients with advanced solid tumors.
Shapiro G, LoRusso P, Vaishampayan U, Kittaneh M, Hilton J, Cleary J, Velastegui K, Xuan D, Hua S, Shazer R, Borghaei H. First-in-human, dose-escalation, safety, and PK study of a novel 5T4-ADC in patients with advanced solid tumors. Journal Of Clinical Oncology 2015, 33: tps2603-tps2603. DOI: 10.1200/jco.2015.33.15_suppl.tps2603.Peer-Reviewed Original Research